Article info

Original research
Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)

Authors

  1. Correspondence to Dr Craig L Slingluff Jr; cls8h{at}virginia.edu
View Full Text

Citation

Vavolizza RD, Petroni GR, Mauldin IS, et al
Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)

Publication history

  • Accepted August 15, 2022
  • First published September 13, 2022.
Online issue publication 
September 13, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.